ExoFlo — Bone Marrow MSC Exosomes for Inflammatory and Respiratory Indications, Phase 2/3
The most advanced late-stage clinical trial among exosome-based therapeutics. Targeting moderate-to-severe COVID-19 ARDS.
| Trial ID | NCT05354141 ↗ |
|---|---|
| Sponsor | Direct Biologics · USA |
| Cell Source | MSC 유래 엑소좀 (MSC-Exo) · allogeneic |
| Indication | 코로나19 ARDS · COVID-19 ARDS |
| Phase | PHASE 2 3 |
| Status | ACTIVE |
| Delivery Route | intravenous infusion (IV) |
| Enrollment | 102 |
| Publication | — |
Trial Design
ExoFlo, developed by Direct Biologics, is an exosome preparation derived from allogeneic bone marrow MSCs, administered by intravenous infusion to patients with moderate-to-severe acute respiratory distress syndrome (ARDS) caused by COVID-19. The EXTINGuISH Phase 2/3 trial represents the leading edge of the exosome field in terms of both enrolment size and stage of development.
Clinical Significance
This trial is one of an extremely rare subset of exosome programs to reach a clinically meaningful development stage. As of 2026, approximately 240 exosome clinical trials have been registered worldwide; however, the overwhelming majority are Phase I or diagnostic in nature, and the number of therapeutics to have reached late-stage Phase 2/3 trials can be counted on one hand.
Reasons for the attention directed at ExoFlo:
- Cell-free therapy — easier to store, transport, and standardise than direct MSC administration
- Anti-inflammatory and immunomodulatory effects — suppression of cytokine storm
- FDA Expanded Access — data accumulated through compassionate use programme
Follow-on Indications
Direct Biologics is pursuing a pipeline to expand ExoFlo’s indications beyond ARDS to include inflammatory bowel disease (IBD), chronic kidney disease (CKD), and neurological disorders.
Limitations and Open Questions
- Difficulty enrolling ARDS patients following the end of the COVID-19 pandemic
- Lack of standardised manufacturing processes and potency assays for exosome products
- Tightening regulatory environment, illustrated by the FDA warning letter issued to industry peer Kimera Labs in 2023
Korean Context
Korean exosome companies are advancing at comparable stages. ILIAS Biologics (ILB-202) and Brexogen, among others, are progressing their own exosome pipelines, with some having received FDA IND approval. The outcome of ExoFlo will have a direct bearing on the credibility of and subsequent investment in the Korean exosome sector as a whole.